|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.00 AUD | +7.84% |
|
+12.70% | -1.79% |
| Capitalization | 3.73B 2.63B 2.27B 2.05B 1.96B 3.56B 242B 24.16B 9.69B 116B 9.86B 9.65B 415B | P/E ratio 2026 * |
-1,470x | P/E ratio 2027 * | 90.8x |
|---|---|---|---|---|---|
| Enterprise value | 4.19B 2.95B 2.55B 2.3B 2.2B 4B 272B 27.14B 10.88B 130B 11.08B 10.84B 467B | EV / Sales 2026 * |
3.09x | EV / Sales 2027 * | 2.63x |
| Free-Float |
58.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Telix Pharmaceuticals Limited
| 1 day | +7.84% | ||
| 1 week | +12.70% | ||
| Current month | +10.00% | ||
| 1 month | +11.56% | ||
| 3 months | -23.18% | ||
| 6 months | -20.41% | ||
| Current year | -1.79% |
| 1 week | 9.35 | 11.62 | |
| 1 month | 8.26 | 11.62 | |
| Current year | 8.26 | 11.99 | |
| 1 year | 8.26 | 29.72 | |
| 3 years | 6.51 | 31.97 | |
| 5 years | 3.55 | 31.97 | |
| 10 years | 0.46 | 31.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 2017-01-02 | |
Darren Smith
DFI | Director of Finance/CFO | 60 | 2022-07-30 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 2017-01-02 | |
Mark Nelson
CHM | Chairman | 66 | 2026-02-02 |
Jann Skinner
BRD | Director/Board Member | 68 | 2018-06-18 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.84% | +12.70% | -60.23% | +52.57% | 2.44B | ||
| +0.36% | -3.16% | -7.79% | -6.03% | 44.96B | ||
| +1.84% | +3.66% | +26.89% | +42.40% | 33.54B | ||
| +0.98% | -13.63% | +16.43% | +43.10% | 30.24B | ||
| -2.71% | -0.69% | -8.49% | -12.42% | 29.97B | ||
| +0.03% | -0.57% | +171.37% | +381.31% | 19.78B | ||
| -0.03% | +0.34% | +73.70% | +125.99% | 14.73B | ||
| -1.59% | +1.13% | +39.49% | +168.29% | 13.58B | ||
| +1.01% | -2.90% | +22.89% | +1.23% | 12.97B | ||
| +0.08% | -4.05% | +134.25% | +122.25% | 12.45B | ||
| Average | +0.79% | -1.11% | +40.85% | +91.87% | 21.46B | |
| Weighted average by Cap. | +0.18% | -1.63% | +35.53% | +71.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.36B 955M 824M 744M 713M 1.3B 88.01B 8.79B 3.52B 42.1B 3.59B 3.51B 151B | 1.6B 1.13B 976M 881M 844M 1.53B 104B 10.4B 4.17B 49.85B 4.25B 4.15B 179B |
| Net income | -2.31M -1.63M -1.4M -1.27M -1.21M -2.21M -150M -14.95M -6M -71.66M -6.1M -5.97M -257M | 31.92M 22.5M 19.41M 17.53M 16.8M 30.53M 2.07B 207M 82.98M 992M 84.46M 82.65M 3.56B |
| Net Debt | 460M 324M 279M 252M 242M 440M 29.85B 2.98B 1.19B 14.28B 1.22B 1.19B 51.24B | 490M 345M 298M 269M 258M 469M 31.81B 3.18B 1.27B 15.22B 1.3B 1.27B 54.61B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-10 | 11.00 $ | +7.84% | 4,690,000 |
| 26-03-09 | 10.20 $ | -5.12% | 3,307,656 |
| 26-03-06 | 10.75 $ | +6.54% | 3,725,239 |
| 26-03-05 | 10.09 $ | +6.55% | 1,821,915 |
| 26-03-04 | 9.470 $ | -4.05% | 5,164,455 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TLX Stock
Select your edition
All financial news and data tailored to specific country editions

















